NGL Fine-Chem (BOM:524774) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524774 NGL Fine-Chem Ltd BOM:524774
69 GF Score
Price ₹3,131.50
GF Value ₹2,857.10
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is NGL Fine-Chem FFO?

FFO (Funds from operations) only applies to REITs.

BOM:524774
69GF Score
NGL Fine-Chem Ltd BOM:524774
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NGL Fine-Chem (BOM:524774) Overvalued in 2026?

Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued. The current stock price of ₹3,131.50 is trading 9.6% above its estimated GF Value™ of ₹2,857.10. GuruFocus considers NGL Fine-Chem to be Fairly Valued.

Key valuation signals for BOM:524774:

  • FFO:
  • GF Value™: ₹2,857.10 vs. price of ₹3,131.50 (9.6% above fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the BOM:524774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NGL Fine-Chem Business Description

Other Exchanges NGLFINE:India
Address 301, E Square, Subhash Road, Vile Parle (East), Mumbai, MH, IND, 400057
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
69GF Score

Get the complete analysis for BOM:524774

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,131.50
Price
₹2,857.10
GF Value